Unlock instant, AI-driven research and patent intelligence for your innovation.

A7R glycopeptide and application thereof in preparation of tumor diagnosis and treatment drug

A glycopeptide and drug technology, applied in the field of A7R glycopeptide and its use in the preparation of tumor diagnosis and treatment drugs, can solve the problems of inability to achieve efficient targeting of brain tumors, reduced targeting ability, poor stability, etc., and achieve good tumor The effect of targeting performance, high stability, and strong anti-tumor effect

Inactive Publication Date: 2019-12-31
FUDAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] A7R (L-type amino acid sequence is L A L T L W L L L P L P L R) is a 7-peptide screened by phage display technology that has high binding activity to vascular endothelial cell growth factor receptor 2 (VEGFR2) and neuropilin-1 (NRP-1), and can target tumor neovascular endothelial cells and Across BTB, tumor mimic blood vessels and tumor cells, it has good targeting ability in vivo; however, A7R, as a polypeptide composed of L-configuration amino acids, has poor stability in vivo and is easily degraded in blood circulation, thus reducing its targeting ability
Although some studies have modified the D-configuration amino acid (the D-type amino acid sequence is D R D P D P D L D W D T D A) Its stability problem has been solved, but it is difficult for A7R to cross the BBB, so it is still unable to achieve efficient targeting of brain tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A7R glycopeptide and application thereof in preparation of tumor diagnosis and treatment drug
  • A7R glycopeptide and application thereof in preparation of tumor diagnosis and treatment drug
  • A7R glycopeptide and application thereof in preparation of tumor diagnosis and treatment drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] A7R glycopeptide, A7R glycopeptide-Fluorescein, A7R glycopeptide-Cy7, A7R glycopeptide-DTPA-Gd, A7R glycopeptide-DTPA- 99m Synthesis and Characterization of Tc, A7R Glycopeptide-drug, A7R Glycopeptide-PEG-DSPE

[0084] 1. Glucosylated threonine Fmoc-Thr(O-β-Glu(OAc) 4 ) synthesis and characterization

[0085] Fmoc-Thr(O-β-Glu(OAc) 4 ) synthesis steps as attached figure 1 As shown, Fmoc-protected threonine (Fmoc-Thr-OH) and peracetylated glucose (2,3,4,6-tetra-O-acetyl-β-D-glucopyranose) were dissolved in CH 2 Cl 2 In ice bath, slowly add BF dropwise 3 ·Et 2 0, until the solution becomes clear, continue to stir under room temperature conditions, and the thin-layer chromatographic plate monitors the degree of reaction (developing agent is CH 2 Cl 2 :CH 3 OH=15:1). Under ice-cooling conditions, an equal volume of 1M hydrochloric acid solution was added dropwise to terminate the reaction. Extract three times, collect the lower organic phase, anhydrous Na 2 SO 4...

Embodiment 2

[0099] Example 2 Investigation of the Serum Stability of A7R Glycopeptides

[0100] Will 9 G-A7R, 9,10 G-A7R and 12 G-A7R was respectively configured into 1 mg / mL PBS solution, 0.1 mL was added to 0.9 mL of 25% rat serum, and then 10 μL of 1% TCEP in EDTA solution was added, placed in a shaker at 37°C and shaken at 100 rpm. Take 0.1mL reaction solution at 0, 0.25, 0.5, 1, 2, 4, 8, 12, and 24h, add 20μL of 15% TCA to precipitate protein, vortex, let stand at 4°C for 20min, centrifuge at 12000rpm for 10min, and take the supernatant 20μL for HPLC qualitative and quantitative analysis, serum stability results (such as Figure 7 shown) shows that, 9 G-A7R, 9,10 G-A7R and 12 G-A7R has better serum stability than A7R.

Embodiment 3

[0101] Example 3 In vitro cell targeting verification of A7R glycopeptide

[0102] In vitro targeting of A7R glycopeptides to brain capillary endothelial cells: Take brain capillary endothelial cells in logarithmic growth phase (bEND.3), digest the monolayer culture cells with 0.25% trypsin, and use 10% fetal bovine serum DMEM culture medium to make a single cell suspension, with 1×10 per well 5 Cells were inoculated in a 12-well culture plate with a volume of 1 mL per well, and the culture plate was moved into a carbon dioxide incubator at 37°C and 5% CO 2 After culturing for 24 hours under the condition of saturated humidity, the concentration of 5μM 9 G-A7R-Fluorescein, 9,10 G-A7R-Fluorescein, 12 For G-A7R-Fluorescein, suck out the culture medium in the culture plate, add the above solution respectively, and incubate at 37°C for 4h. Wash three times with PBS solution, fix the cells with formaldehyde fixative, stain the cell nucleus with DAPI, observe the cell uptake by ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention belongs to the pharmacy field and relates to A7R glycopeptide, preparation of an A7R glycopeptide modified drugs and polymer carrier materials as well as application of the A7R glycopeptide in tumor images and construction of a drug delivery system for targeted therapy. Results show that the A7R glycopeptide retains the capacity of A7R polypeptide for targeting new vascular endothelial cells of tumor and crossing a blood-tumor barrier (BTB) to target tumor mimesis blood vessels and tumor cells, the stability of polypeptide in vivo is also enhanced, meanwhile, the polypeptide hasa function of targeting brain capillary endothelial cells and crossing a blood-brain barrier (BBB), and the targeting ability of the polypeptide for tumor is significantly improved; and A7R glycopeptide modified drugs or nano drug delivery systems such as lipid discs, lipidosome, polymeric micelles and nanoparticles can all cross the BBB and the BTB, coated drugs can be delivered to tumor tissue,and the diagnosis and treatment effects on the tumor can be remarkably improved. The A7R glycopeptides can mediate drugs or nano drug delivery system to initiatively seek targets, and has good application prospects in diagnosis and targeted therapy of tumor.

Description

technical field [0001] The present invention belongs to the field of pharmacy, relates to A7R glycopeptide and its use in pharmacy, specifically relates to A7R glycopeptide and its modified diagnostic and therapeutic drug complex, modified polymer carrier material and its constructed liposome, polymer Nano drug delivery systems such as micelles, polymer discs, and nanoparticles, and their applications in the preparation of drugs for the diagnosis and targeted therapy of brain tumors or peripheral tumors. The A7R glycopeptide, its drug complex and the modified nano drug delivery system have high stability, cross the blood-brain barrier (BBB) ​​and blood-tumor barrier (BTB), and target tumor neovascularization, tumor-mimicking blood vessels and Multifunctional targeting features of tumor cells. Background technique [0002] The report discloses that tumor is a disease that seriously threatens human life and health, and its mortality rate ranks first among all diseases. As th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K9/00A61K45/00A61K47/42A61P35/00
CPCC07K9/00C07K9/001A61K47/42A61K45/00A61P35/00
Inventor 陆伟跃王欢谢操李欢
Owner FUDAN UNIV